Dr. Hulihan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
201 N Congress St
Newtown, PA 18940Phone+1 215-497-7472
Education & Training
Drexel University College of Medicine/Hahnemann University HospitalResidency, Neurology, 1987 - 1990- Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 1986 - 1987
- Drexel University College of MedicineClass of 1986
Certifications & Licensure
PA State Medical License 1988 - 2022
MN State Medical License 1990 - 1991- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 335 citationsEfficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.Stephen D. Silberstein, Richard B. Lipton, David W. Dodick, Frederick G. Freitag, Nabih M. Ramadan
Headache. 2007-02-01 - 95 citationsTopiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult mi...David W. Dodick, Frederick G. Freitag, James Banks, Joel Saper, Jim Xiang
Clinical Therapeutics. 2009-03-01 - 55 citationsThe impact of topiramate on health-related quality of life indicators in chronic migraineDavid W. Dodick, Stephen D. Silberstein, Joel Saper, Frederick G. Freitag, Roger Cady
Headache. 2007-11-01
Press Mentions
Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline UpdateAugust 3rd, 2021- Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect ConferenceJanuary 6th, 2021
- Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD)July 30th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
